Thirty-six million Americans and hundreds of millions globally currently suffer from hearing loss, a condition with profound health impacts for patients that are responsible for an estimated $122B in annual economic losses in the U.S. alone. JBI is actively developing novel small molecule compounds to prevent, halt and/or mitigate a broad range of hearing loss indications, including noise-induced hearing loss and hearing loss caused by exposure to ototoxic agents such as cisplatin and aminoglycosides. JBI’s founders demonstrated that dysregulation of the unfolded protein response (UPR) after noise and ototoxic exposures is implicated in the pathophysiology of hearing loss. JBI’s therapeutics modulate the UPR and, as demonstrated via in vitro and in vivo experimentation, have the potential to significantly reduce hearing loss and its deleterious consequences.